Method for generating avid-binding multispecific antibodies

Patent metadata

Field	Value
Publication number	US-12565536-B2
Application number	US-202117488698-A
Country	US
Kind code	B2
Filing date	Sep 29, 2021
Priority date	Mar 29, 2019
Publication date	Mar 3, 2026
Grant date	Mar 3, 2026

Abstract

Herein is reported a method for increasing the (avid-)binding specificity of a bispecific antibody comprising a first mammalian or mammalianized binding site specifically binding to a first (cell-surface) antigen and a second binding site specifically binding to a second (cell-surface) antigen, wherein the first mammalian or mammalianized binding site is at least a pair of an immunoglobulin light chain variable domain and immunoglobulin heavy chain variable domain, by decreasing the binding affinity of the mammalian or mammalianized binding site to its antigen by mutating in the first mammalian or mammalianized binding site at least one amino acid residue at a position in the CDRs of the light chain variable domain or in the CDR1 or CDR2 of the heavy chain variable domain or in the two framework positions directly preceding the CDR3 in the heavy chain variable domain to an amino acid residue present at said position in a germline immunoglobulin amino acid sequence of the same mammalian species as that of the mammalian or mammalianized binding site.

First claim

The invention claimed is:

1 . A method for decreasing the binding affinity of a bispecific antibody comprising a first binding site specifically binding to a first cell-surface antigen and a second binding site specifically binding to a second cell-surface antigen, with said first and second antigen being on the same cell,
wherein the first binding site is a mammalian or mammalianized binding site, wherein the first binding site is at least a pair of an immunoglobulin light chain variable domain and an immunoglobulin heavy chain variable domain, wherein the decreasing the binding affinity is a decreasing of the binding affinity of the first binding site to its antigen by mutating in the first binding site at least one amino acid residue at a position in the CDRs of the light chain variable domain or in the CDR1 or CDR2 of the heavy chain variable domain or in the two framework positions directly preceding the CDR3 in the heavy chain variable domain to an amino acid residue present at said position in a germline variable domain immunoglobulin amino acid sequence of the same mammalian species as that of the mammalian or mammalianized binding site, wherein the germline variable domain immunoglobulin amino acid sequence has the highest identity of all germline variable domain immunoglobulin amino acid sequences of the mammalian species to the respective light or heavy chain variable domain of the first binding site of the bispecific antibody, based on a sequence alignment of said all germline variable domain immunoglobulin amino acid sequences of the mammalian species to the respective light or heavy chain variable domain of the first binding site of the bispecific antibody, and wherein the mutated mammalian or mammalianized binding site is free of polyreactivity.

2 . The method according to claim 1 ,
wherein the germline variable domain immunoglobulin amino acid sequence is a germline heavy chain variable domain immunoglobulin amino acid sequence, wherein the germline variable domain immunoglobulin amino acid sequence has the highest identity of all germline heavy chain variable domain immunoglobulin amino acid sequences of the mammalian species to the heavy chain variable domain of the first binding site of the bispecific antibody, based on a sequence alignment of all germline heavy chain variable domain immunoglobulin amino acid sequences to the respective heavy chain variable domain sequence of the first binding site of the bispecific antibody, and wherein the heavy chain variable domain sequences used for the alignment span the first residue of CDR1 of the heavy chain variable domain to the last residue of the CDR2 of the heavy chain variable domain.

3 . The method according to claim 1 or 2 , wherein the side-chains of the amino acid residues to be mutated are solvent accessible.

4 . The method according to claim 1 or 2 , wherein the side-chains of the amino acid residues to be mutated are not involved in a VH-VL interactions.

5 . The method according to claim 1 or 2 , wherein the side-chains of the amino acid residues to be mutated are involved in interactions with the antigen.

6 . The method according to claim 1 or 2 , wherein the method further comprises mutating at least one amino acid residue in the second mammalian or mammalianized binding site, wherein the second binding site is at least a second pair of an immunoglobulin light chain variable domain and an immunoglobulin heavy chain variable domain, or the second binding site is a second mammalian or mammalianized binding site and the mutating is of at least one amino acid residue in the first and the second mammalian, or mammalianized binding site.

7 . The method according to claim 1 or 2 , wherein the mammal is a human.

Assignees

• Hoffmann La Roche

Inventors

• Brinkmann Ulrich
• Bujotzek Alexander
• Georges Guy
• Schrade Anja

Classifications

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K2317/31

  multispecific · CPC title

• C07K16/2896

  against molecules with a "CD"-designation, not provided for elsewhere · CPC title

• C07K16/2863

  against receptors for growth factors, growth regulators · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title